Breast cancer: Biology, biomarkers, and treatments

被引:489
作者
Barzaman, Khadijeh [1 ,2 ]
Karami, Jafar [1 ,3 ]
Zarei, Zeinab [4 ]
Hosseinzadeh, Aysooda [2 ]
Kazemi, Mohammad Hossein [5 ,6 ]
Moradi-Kalbolandi, Shima [2 ]
Safari, Elahe [1 ,7 ]
Farahmand, Leila [2 ]
机构
[1] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[2] ACECR, Motamed Canc Inst, Recombinant Prot Dept, Breast Canc Res Ctr, Tehran, Iran
[3] Univ Tehran Med Sci, Rheumatol Res Ctr, Tehran, Iran
[4] ACECR, Motamed Canc Inst, Dept Biomat & Tissue Engn, Breast Canc Res Ctr, Tehran, Iran
[5] Iran Univ Med Sci, Sch Med, Dept Immunol, Student Res Comm, Tehran, Iran
[6] ACECR, Motamed Canc Inst, ATMP Dept, Breast Canc Res Ctr, Tehran, Iran
[7] Iran Univ Med Sci, Immunol Res Ctr, Tehran, Iran
关键词
Breast cancer; Treatment; Nanoparticles; Antibody-drug conjugation systems; Breast cancer stem cells; Immunotherapy; MESENCHYMAL STEM-CELLS; ESTROGEN-RECEPTOR; METRONOMIC CHEMOTHERAPY; PROGESTERONE-RECEPTOR; CLINICAL UTILITY; PROGNOSTIC-FACTORS; THERAPY; RESISTANCE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.1016/j.intimp.2020.106535
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer stem cells (BCSCs) are the main player in the aggressiveness of different tumors and also, these cells are the main challenge in cancer treatment. Moreover, the major obstacle to achieve an effective treatment is resistance to therapies. There are various types of treatment for breast cancer (BC) patients. Therefore, in this review, we present the current treatments, novel approaches such as antibody-drug conjugation systems (ADCs), nanoparticles (albumin-, metal-, lipid-, polymer-, micelle-based nanoparticles), and BCSCs-based therapies. Furthermore, prognostic and predictive biomarkers will be discussed also biomarkers that have been applied by some tests such as Oncotype DX, Mamm aPrint, and uPA/PAI-1 are regarded as suitable prognostic and predictive factors in breast cancer.
引用
收藏
页数:10
相关论文
共 146 条
[51]  
El Hout M., 2018, PROMISING NEW APPROA
[52]   Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape [J].
Emens, Leisha A. ;
Ascierto, Paolo A. ;
Darcy, Phillip K. ;
Demaria, Sandra ;
Eggermont, Alexander M. M. ;
Redmond, William L. ;
Seliger, Barbara ;
Marincola, Francesco M. .
EUROPEAN JOURNAL OF CANCER, 2017, 81 :116-129
[53]   Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis [J].
Eyler, Christine E. ;
Rich, Jeremy N. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (17) :2839-2845
[54]   Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].
Galluzzi, Lorenzo ;
Buque, Aitziber ;
Kepp, Oliver ;
Zitvogel, Laurence ;
Kroemer, Guido .
CANCER CELL, 2015, 28 (06) :690-714
[55]   The secret ally: immunostimulation by anticancer drugs [J].
Galluzzi, Lorenzo ;
Senovilla, Laura ;
Zitvogel, Laurence ;
Kroemer, Guido .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) :215-233
[56]   In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles [J].
Gao, Huile ;
Chen, Chen ;
Xi, Zhangjie ;
Chen, Jun ;
Zhang, Qizhi ;
Cao, Shilei ;
Jiang, Xinguo .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2013, 14 (12) :1062-1071
[57]   Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment [J].
Garcia-Pinel, Beatriz ;
Porras-Alcala, Cristina ;
Ortega-Rodriguez, Alicia ;
Sarabia, Francisco ;
Prados, Jose ;
Melguizo, Consolacion ;
Lopez-Romero, Juan M. .
NANOMATERIALS, 2019, 9 (04)
[58]  
Goli N., 2018, J DRUG DELIVERY SCI
[59]   Prospects for combining targeted and conventional cancer therapy with immunotherapy [J].
Gotwals, Philip ;
Cameron, Scott ;
Cipolletta, Daniela ;
Cremasco, Viviana ;
Crystal, Adam ;
Hewes, Becker ;
Mueller, Britta ;
Quaratino, Sonia ;
Sabatos-Peyton, Catherine ;
Petruzzelli, Lilli ;
Engelman, Jeffrey A. ;
Dranoff, Glenn .
NATURE REVIEWS CANCER, 2017, 17 (05) :286-301
[60]   Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].
Harris, Lyndsay N. ;
Ismaila, Nofisat ;
McShane, Lisa M. ;
Andre, Fabrice ;
Collyar, Deborah E. ;
Gonzalez-Angulo, Ana M. ;
Hammond, Elizabeth H. ;
Kuderer, Nicole M. ;
Liu, Minetta C. ;
Mennel, Robert G. ;
Van Poznak, Catherine ;
Bast, Robert C. ;
Hayes, Daniel F. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1134-+